Skip to content
Medical Health Aged Care

Galderma launches new ALASTIN Restorative Skin Complex with Next Generation TriHex Technology®

Galderma Group AG 3 mins read

ALASTIN by Galderma, a leader in professional grade skincare, unveils its latest innovation clinically proven to help rejuvenate skin


ZUG, Switzerland--BUSINESS WIRE--

Galderma Group AG (SWX:GALD), the pure-play dermatology category leader, announced today that ALASTIN, a leader in medical-grade peptide-based regenerative skincare, has officially launched their latest skincare innovation with the introduction of Restorative Skin Complex with Next Generation TriHex Technology® (TriHex+™). This newly enhanced formula can be used as a multi-functional, daily rejuvenating serum to support the skin’s natural collagen and elastin production that declines from aging as well as the visible loss of volume in skin impacted by factors such as facial aging or medication-driven weight loss. Restorative Skin Complex with TriHex+ joins ALASTIN’s other world class and award-winning products that are science-led and physician-endorsed.

The much-loved Restorative Skin Complex formula has been enhanced with two groundbreaking additions. The first is an innovation to the patented TriHex Technology with the addition of Octapeptide-45, a proprietary, patent-pending peptide that amplifies the skin’s natural ability to regenerate collagen and elastin addressing the appearance of fine lines, radiance, skin plumping and long-lasting hydration. In addition, the new formula includes a novel ingredient, Magnolol, which helps stimulate depleted fat tissue (adipocytes). These new ingredients help to visibly restore desired facial radiance and plumping by supporting the skin’s own regenerative abilities that decline as we age, especially from age of 25 and up, when we begin losing around 1% of our collagen a year.1

 Galderma’s team is constantly evaluating unmet skin care needs and how we can elevate our products to address them. Concerns like loss of collagen and elasticity, along with the loss of volume as a result of medication-driven weight loss or other factors, have been at the forefront of patient concerns with their skin specialists. We knew we had to do more to help restore their ‘good fat’ while also regenerating the collagen and elastin that can degrade over time.”

 

ALAN D. WIDGEROW, MBBCH, MMED, FCS, FACS

CHIEF SCIENTIFIC OFFICER GALDERMA, HEAD SKIN SCIENCE
CENTER FOR INNOVATION, HEAD ALASTIN INNOVATIONS

 

ALASTIN will be launching the newly enhanced Restorative Skin Complex with TriHex+ this month in the United States. It will be available exclusively from authorized ALASTIN skincare providers at dermatology offices, clinics and medispas. Galderma is working to bring this new innovation to other international markets where ALASTIN is already available.

 Adding ingredients to further support the appearance of elasticity and skin volumization to a much-loved product that already delivers anti-aging, hydration, and visible volume facial plumping benefits represents a significant clinical and scientific breakthrough.”

 

DEANNE MRAZ, MD, FAAD

PRESIDENT AND FOUNDER, DMR RESEARCH

PRESIDENT AND CO-FOUNDER, MODERN DERMATOLOGY

ASSISTANT CLINICAL PROFESSOR OF DERMATOLOGY, YALE NEW HAVEN HOSPITAL

 

About Galderma

Galderma (SWX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

15 Signs Your Skin Is Losing Collagen | Vogue


Contact details:

For further information:

Christian Marcoux, M.Sc.
Chief Communications Officer
[email protected]
+41 76 315 26 50

Richard Harbinson
Corporate Communications Director
[email protected]
+41 76 210 60 62

Jeffrey Smith
Head of U.S. Communications
[email protected]
+1 (682) 401-8428

Media

More from this category

  • CharitiesAidWelfare, Medical Health Aged Care
  • 17/12/2025
  • 06:00
Leukaemia Foundation

Leukaemia Foundation welcomes South Australian Government commitment to establish dedicated CAR T therapy service

The Leukaemia Foundation has welcomed the announcement by theMalinauskas Labor Government that South Australia is establishing a dedicated CAR T-cell therapy service as a line of treatment for people living with blood cancer – marking a major advancement in cancer care in the State. The new service, expected to commence by mid-2026, will significantly improve access to this highly specialised, life-saving treatment and reduce the need for South Australians to travel interstate for care. Leukaemia Foundation Chief Executive Officer Chris Tanti said the announcement represented a huge win for blood cancer patients and their families. “This is a landmark step…

  • Medical Health Aged Care
  • 17/12/2025
  • 01:10
WW International Inc.

Weight Watchers Launches a Fully Integrated Platform for the GLP-1 Era

A redesigned Weight Watchers experience pairs comprehensive GLP-1 support with personalised nutrition, coaching, community support, and cutting-edge technology to help members meet their weight loss goals and achieve results that lastNEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight management, today introduced a new, fully integrated experience bringing together comprehensive support for members on GLP-1 medications, personalised nutrition, behavioural support, coaching, and community within a redesigned app and digital platform. Built for a new era of weight management and long-term health, the new integrated offering delivers coordinated, evidence-based…

  • Medical Health Aged Care
  • 16/12/2025
  • 12:11
Esco Aster Pte. Ltd.

Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform

SINGAPORE–BUSINESS WIRE– Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.